BG67567B1 - Метод за количествена оценка за бързо прогнозиране и контрол на дисбиози при кърмачета на възраст от един месец до една година - Google Patents

Метод за количествена оценка за бързо прогнозиране и контрол на дисбиози при кърмачета на възраст от един месец до една година Download PDF

Info

Publication number: BG67567B1
Authority: BG; Bulgaria
Prior art keywords: breast milk; sample; feces; infant; dysbiosis
Prior art date: 2020-05-27

Application number

BG113148A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG113148A (bg

Inventor

Илия ИЛИЕВ

Николов Илиев Илия

Деян Прокопов

Крумов Прокопов Деян

Вълко Калинкин

Иванов Калинкин Вълко

Тонка Василева

Атанасова Василева Тонка

Веселин Биволарски

Петров Биволарски Веселин

Мариана Николова

Манолова Николова Мариана

Даниела Моллова

Георгиева Моллова Даниела

Original Assignee

Гама Консулт-Калинкин, Прокопов И С-Ие Сд

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2020-05-27

Filing date

2020-05-27

Publication date

2023-09-15

2020-05-27 Application filed by Гама Консулт-Калинкин, Прокопов И С-Ие Сд filed Critical Гама Консулт-Калинкин, Прокопов И С-Ие Сд

2020-05-27 Priority to BG113148A priority Critical patent/BG67567B1/bg

2020-05-28 Priority to EP20742153.8A priority patent/EP4162081A1/fr

2020-05-28 Priority to PCT/BG2020/050001 priority patent/WO2021237312A1/fr

2021-12-15 Publication of BG113148A publication Critical patent/BG113148A/bg

2023-09-15 Publication of BG67567B1 publication Critical patent/BG67567B1/bg

Links

238000000034 method Methods 0.000 title claims abstract description 29
230000007140 dysbiosis Effects 0.000 title claims abstract description 23
208000027244 Dysbiosis Diseases 0.000 title claims abstract description 21
210000000481 breast Anatomy 0.000 title abstract 2
235000020256 human milk Nutrition 0.000 claims abstract description 56
210000004251 human milk Anatomy 0.000 claims abstract description 56
230000000694 effects Effects 0.000 claims abstract description 51
102000004190 Enzymes Human genes 0.000 claims abstract description 47
108090000790 Enzymes Proteins 0.000 claims abstract description 47
244000005700 microbiome Species 0.000 claims abstract description 26
239000002207 metabolite Substances 0.000 claims abstract description 25
210000003608 fece Anatomy 0.000 claims abstract description 23
239000000203 mixture Substances 0.000 claims abstract description 15
238000000338 in vitro Methods 0.000 claims abstract description 9
238000010521 absorption reaction Methods 0.000 claims abstract description 7
241000736262 Microbiota Species 0.000 claims description 21
239000000090 biomarker Substances 0.000 claims description 8
238000012545 processing Methods 0.000 claims description 6
230000008774 maternal effect Effects 0.000 claims 1
238000013178 mathematical model Methods 0.000 claims 1
229920001542 oligosaccharide Polymers 0.000 abstract description 21
150000002482 oligosaccharides Chemical class 0.000 abstract description 21
102000004169 proteins and genes Human genes 0.000 abstract description 15
108090000623 proteins and genes Proteins 0.000 abstract description 15
238000013459 approach Methods 0.000 abstract description 7
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract description 6
230000000968 intestinal effect Effects 0.000 abstract description 6
239000008101 lactose Substances 0.000 abstract description 6
230000004060 metabolic process Effects 0.000 abstract description 6
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract description 5
150000002632 lipids Chemical class 0.000 abstract description 5
238000004364 calculation method Methods 0.000 abstract description 4
238000003745 diagnosis Methods 0.000 abstract description 2
230000005484 gravity Effects 0.000 abstract 1
229940088598 enzyme Drugs 0.000 description 41
239000000523 sample Substances 0.000 description 40
238000001514 detection method Methods 0.000 description 35
230000001580 bacterial effect Effects 0.000 description 34
241000186000 Bifidobacterium Species 0.000 description 33
241000894006 Bacteria Species 0.000 description 29
238000006243 chemical reaction Methods 0.000 description 28
241000186660 Lactobacillus Species 0.000 description 26
238000011529 RT qPCR Methods 0.000 description 25
150000004666 short chain fatty acids Chemical class 0.000 description 19
235000021391 short chain fatty acids Nutrition 0.000 description 18
238000004458 analytical method Methods 0.000 description 17
210000004027 cell Anatomy 0.000 description 16
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
241000894007 species Species 0.000 description 15
235000018102 proteins Nutrition 0.000 description 14
210000001035 gastrointestinal tract Anatomy 0.000 description 12
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
238000011002 quantification Methods 0.000 description 12
108010005774 beta-Galactosidase Proteins 0.000 description 11
102000005936 beta-Galactosidase Human genes 0.000 description 11
BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 10
239000007850 fluorescent dye Substances 0.000 description 10
239000012634 fragment Substances 0.000 description 10
241000606125 Bacteroides Species 0.000 description 9
108091005804 Peptidases Proteins 0.000 description 9
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 9
108010061314 alpha-L-Fucosidase Proteins 0.000 description 9
102000012086 alpha-L-Fucosidase Human genes 0.000 description 9
238000006911 enzymatic reaction Methods 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
244000005709 gut microbiome Species 0.000 description 9
244000005706 microflora Species 0.000 description 9
239000000243 solution Substances 0.000 description 9
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
239000008267 milk Substances 0.000 description 8
210000004080 milk Anatomy 0.000 description 8
239000006228 supernatant Substances 0.000 description 8
IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 7
239000004365 Protease Substances 0.000 description 7
201000010099 disease Diseases 0.000 description 7
229940039696 lactobacillus Drugs 0.000 description 7
235000013336 milk Nutrition 0.000 description 7
102000011632 Caseins Human genes 0.000 description 6
108010076119 Caseins Proteins 0.000 description 6
208000006673 asthma Diseases 0.000 description 6
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 6
235000021240 caseins Nutrition 0.000 description 6
235000021277 colostrum Nutrition 0.000 description 6
210000003022 colostrum Anatomy 0.000 description 6
235000005911 diet Nutrition 0.000 description 6
230000002550 fecal effect Effects 0.000 description 6
238000004128 high performance liquid chromatography Methods 0.000 description 6
239000004310 lactic acid Substances 0.000 description 6
235000014655 lactic acid Nutrition 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
YILIDCGSXCGACV-SQKFTNEHSA-N 4-nitrophenyl alpha-L-fucoside Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1OC1=CC=C([N+]([O-])=O)C=C1 YILIDCGSXCGACV-SQKFTNEHSA-N 0.000 description 5
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 5
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
240000004808 Saccharomyces cerevisiae Species 0.000 description 5
235000011054 acetic acid Nutrition 0.000 description 5
238000003556 assay Methods 0.000 description 5
230000009286 beneficial effect Effects 0.000 description 5
239000000872 buffer Substances 0.000 description 5
239000005018 casein Substances 0.000 description 5
238000011161 development Methods 0.000 description 5
230000037213 diet Effects 0.000 description 5
239000012153 distilled water Substances 0.000 description 5
244000005702 human microbiome Species 0.000 description 5
241000193403 Clostridium Species 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
102000004882 Lipase Human genes 0.000 description 4
108090001060 Lipase Proteins 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
239000011543 agarose gel Substances 0.000 description 4
108010030291 alpha-Galactosidase Proteins 0.000 description 4
102000005840 alpha-Galactosidase Human genes 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
238000001962 electrophoresis Methods 0.000 description 4
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 4
229960005542 ethidium bromide Drugs 0.000 description 4
230000036541 health Effects 0.000 description 4
238000002955 isolation Methods 0.000 description 4
230000000813 microbial effect Effects 0.000 description 4
125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 4
230000008569 process Effects 0.000 description 4
238000004445 quantitative analysis Methods 0.000 description 4
229910000029 sodium carbonate Inorganic materials 0.000 description 4
235000011149 sulphuric acid Nutrition 0.000 description 4
229960004441 tyrosine Drugs 0.000 description 4
IFBHRQDFSNCLOZ-IIRVCBMXSA-N 4-nitrophenyl-α-d-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-IIRVCBMXSA-N 0.000 description 3
206010003645 Atopy Diseases 0.000 description 3
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
239000004367 Lipase Substances 0.000 description 3
102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 3
208000037656 Respiratory Sounds Diseases 0.000 description 3
206010047924 Wheezing Diseases 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
239000008351 acetate buffer Substances 0.000 description 3
HMQPEDMEOBLSQB-RCBHQUQDSA-N beta-D-Galp-(1->3)-alpha-D-GlcpNAc Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HMQPEDMEOBLSQB-RCBHQUQDSA-N 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
239000007979 citrate buffer Substances 0.000 description 3
238000007865 diluting Methods 0.000 description 3
229930191176 lacto-N-biose Natural products 0.000 description 3
235000019421 lipase Nutrition 0.000 description 3
238000011160 research Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
PKAUICCNAWQPAU-UHFFFAOYSA-N 2-(4-chloro-2-methylphenoxy)acetic acid;n-methylmethanamine Chemical compound CNC.CC1=CC(Cl)=CC=C1OCC(O)=O PKAUICCNAWQPAU-UHFFFAOYSA-N 0.000 description 2
IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 4-nitrophenyl alpha-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
101000984736 Agkistrodon piscivorus piscivorus Bradykinin-potentiating peptide F Proteins 0.000 description 2
241001608472 Bifidobacterium longum Species 0.000 description 2
208000017667 Chronic Disease Diseases 0.000 description 2
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
241000588921 Enterobacteriaceae Species 0.000 description 2
241000233866 Fungi Species 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
150000008493 L-fucopyranosides Chemical class 0.000 description 2
102000014171 Milk Proteins Human genes 0.000 description 2
108010011756 Milk Proteins Proteins 0.000 description 2
108010014251 Muramidase Proteins 0.000 description 2
102000016943 Muramidase Human genes 0.000 description 2
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
238000010818 SYBR green PCR Master Mix Methods 0.000 description 2
244000269722 Thea sinensis Species 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
239000013504 Triton X-100 Substances 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
239000008272 agar Substances 0.000 description 2
238000000246 agarose gel electrophoresis Methods 0.000 description 2
108010028144 alpha-Glucosidases Proteins 0.000 description 2
102000006995 beta-Glucosidase Human genes 0.000 description 2
108010047754 beta-Glucosidase Proteins 0.000 description 2
230000000975 bioactive effect Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000001013 cariogenic effect Effects 0.000 description 2
230000001332 colony forming effect Effects 0.000 description 2
LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
208000002925 dental caries Diseases 0.000 description 2
239000012149 elution buffer Substances 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
235000019439 ethyl acetate Nutrition 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
239000000499 gel Substances 0.000 description 2
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
230000009545 invasion Effects 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
229920006008 lipopolysaccharide Polymers 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
239000004325 lysozyme Substances 0.000 description 2
235000010335 lysozyme Nutrition 0.000 description 2
229960000274 lysozyme Drugs 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
229940054192 micro-guard Drugs 0.000 description 2
235000021239 milk protein Nutrition 0.000 description 2
210000000214 mouth Anatomy 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
-1 p-nitrophenol α-D-glucopyranoside Chemical class 0.000 description 2
LVZSQWIWCANHPF-UHFFFAOYSA-N p-nitrophenyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC1=CC=C([N+]([O-])=O)C=C1 LVZSQWIWCANHPF-UHFFFAOYSA-N 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
230000008092 positive effect Effects 0.000 description 2
235000019260 propionic acid Nutrition 0.000 description 2
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
238000003753 real-time PCR Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000007974 sodium acetate buffer Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
OBHRVMZSZIDDEK-UHFFFAOYSA-N urobilinogen Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(CC3C(=C(CC)C(=O)N3)C)N2)CCC(O)=O)N1 OBHRVMZSZIDDEK-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000030090 Acute Disease Diseases 0.000 description 1
241001148536 Bacteroides sp. Species 0.000 description 1
241000186016 Bifidobacterium bifidum Species 0.000 description 1
241000186012 Bifidobacterium breve Species 0.000 description 1
239000002028 Biomass Substances 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
241001112696 Clostridia Species 0.000 description 1
241001430149 Clostridiaceae Species 0.000 description 1
208000002881 Colic Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
241000238557 Decapoda Species 0.000 description 1
241000305071 Enterobacterales Species 0.000 description 1
208000005577 Gastroenteritis Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
102000010445 Lactoferrin Human genes 0.000 description 1
108010063045 Lactoferrin Proteins 0.000 description 1
241001453171 Leptotrichia Species 0.000 description 1
108090000301 Membrane transport proteins Proteins 0.000 description 1
102000003939 Membrane transport proteins Human genes 0.000 description 1
206010051606 Necrotising colitis Diseases 0.000 description 1
208000031662 Noncommunicable disease Diseases 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
206010036590 Premature baby Diseases 0.000 description 1
241000605861 Prevotella Species 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
241000295644 Staphylococcaceae Species 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
241000194019 Streptococcus mutans Species 0.000 description 1
240000007591 Tilia tomentosa Species 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 description 1
241001148134 Veillonella Species 0.000 description 1
241001430183 Veillonellaceae Species 0.000 description 1
AVMNFQHJOOYCAP-UHFFFAOYSA-N acetic acid;propanoic acid Chemical compound CC(O)=O.CCC(O)=O AVMNFQHJOOYCAP-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
HMQPEDMEOBLSQB-UFLFEMAHSA-N beta-D-Galp-(1->3)-beta-D-GalpNAc Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HMQPEDMEOBLSQB-UFLFEMAHSA-N 0.000 description 1
AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
238000010170 biological method Methods 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
235000020299 breve Nutrition 0.000 description 1
150000004652 butanoic acids Chemical class 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
229940021722 caseins Drugs 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000019771 cognition Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000007123 defense Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000003398 denaturant Substances 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
235000013325 dietary fiber Nutrition 0.000 description 1
235000021004 dietary regimen Nutrition 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
239000012470 diluted sample Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000003746 feather Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
UBLXEEBHYISRFM-UHFFFAOYSA-M folin's reagent Chemical compound [Na+].C1=CC=C2C(S(=O)(=O)[O-])=CC(=O)C(=O)C2=C1 UBLXEEBHYISRFM-UHFFFAOYSA-M 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
230000033581 fucosylation Effects 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
235000013376 functional food Nutrition 0.000 description 1
108010081954 galacto-N-biose Proteins 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
230000007366 host health Effects 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
QCQYVCMYGCHVMR-UHFFFAOYSA-N lacto-N-biose I Natural products CC(=O)NC(C=O)C(C(O)C(O)CO)OC1OC(CO)C(O)C(O)C1O QCQYVCMYGCHVMR-UHFFFAOYSA-N 0.000 description 1
108010088312 lacto-N-biosidase Proteins 0.000 description 1
USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 description 1
235000021242 lactoferrin Nutrition 0.000 description 1
229940078795 lactoferrin Drugs 0.000 description 1
229940046892 lead acetate Drugs 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
235000019626 lipase activity Nutrition 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000004066 metabolic change Effects 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
208000004995 necrotizing enterocolitis Diseases 0.000 description 1
HVFSJXUIRWUHRG-UHFFFAOYSA-N oic acid Natural products C1CC2C3CC=C4CC(OC5C(C(O)C(O)C(CO)O5)O)CC(O)C4(C)C3CCC2(C)C1C(C)C(O)CC(C)=C(C)C(=O)OC1OC(COC(C)=O)C(O)C(O)C1OC(C(C1O)O)OC(COC(C)=O)C1OC1OC(CO)C(O)C(O)C1O HVFSJXUIRWUHRG-UHFFFAOYSA-N 0.000 description 1
239000008188 pellet Substances 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000006041 probiotic Substances 0.000 description 1
235000018291 probiotics Nutrition 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000000092 prognostic biomarker Substances 0.000 description 1
230000004224 protection Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000009979 protective mechanism Effects 0.000 description 1
230000005180 public health Effects 0.000 description 1
238000011158 quantitative evaluation Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
239000013049 sediment Substances 0.000 description 1
230000009450 sialylation Effects 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/10—Enterobacteria
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Analytical Chemistry (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Physics & Mathematics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Toxicology (AREA)
Pathology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

BG113148A 2020-05-27 2020-05-27 Метод за количествена оценка за бързо прогнозиране и контрол на дисбиози при кърмачета на възраст от един месец до една година BG67567B1 (bg)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
BG113148A BG67567B1 (bg)	2020-05-27	2020-05-27	Метод за количествена оценка за бързо прогнозиране и контрол на дисбиози при кърмачета на възраст от един месец до една година
EP20742153.8A EP4162081A1 (fr)	2020-05-27	2020-05-28	Procédé d'évaluation quantitative (mqe à la fois pour le pronostic rapide de la dysbiose chez les nourrissons jusqu'à l'âge de 1 an (mqe/rpdi-1y), et pour des maladies multifactorielles (mqe/mfd)
PCT/BG2020/050001 WO2021237312A1 (fr)	2020-05-27	2020-05-28	Procédé d'évaluation quantitative (mqe à la fois pour le pronostic rapide de la dysbiose chez les nourrissons jusqu'à l'âge de 1 an (mqe/rpdi-1y), et pour des maladies multifactorielles (mqe/mfd)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
BG113148A BG67567B1 (bg)	2020-05-27	2020-05-27	Метод за количествена оценка за бързо прогнозиране и контрол на дисбиози при кърмачета на възраст от един месец до една година

Publications (2)

Publication Number	Publication Date
BG113148A BG113148A (bg)	2021-12-15
BG67567B1 true BG67567B1 (bg)	2023-09-15

Family

ID=71661600

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG113148A BG67567B1 (bg)	2020-05-27	2020-05-27	Метод за количествена оценка за бързо прогнозиране и контрол на дисбиози при кърмачета на възраст от един месец до една година

Country Status (3)

Country	Link
EP (1)	EP4162081A1 (fr)
BG (1)	BG67567B1 (fr)
WO (1)	WO2021237312A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT202200008705A1 (it) *	2022-04-29	2023-10-29	Wellmicro S R L	Metodo per determinare una funzionalita’ metabolica di una popolazione batterica e apparato per eseguire detto metodo

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20160243138A1 (en) *	2014-10-29	2016-08-25	Glycom A/S	Composition comprising HMSs/HMOs and use thereof
MX2018015725A (es) *	2016-07-01	2019-09-09	Evolve Biosystems Inc	Método para facilitar la maduración del sistema inmunitario de mamíferos.
WO2018106845A1 (fr) *	2016-12-06	2018-06-14	Kaleido Biosciences, Inc.	Polymères glycane et procédés associés
US11666611B2 (en) *	2017-12-11	2023-06-06	The Brigham And Women's Hospital, Inc.	Defined therapeutic microbiota and methods of use thereof

2020
- 2020-05-27 BG BG113148A patent/BG67567B1/bg unknown
- 2020-05-28 WO PCT/BG2020/050001 patent/WO2021237312A1/fr not_active Ceased
- 2020-05-28 EP EP20742153.8A patent/EP4162081A1/fr active Pending

Also Published As

Publication number	Publication date
WO2021237312A1 (fr)	2021-12-02
EP4162081A1 (fr)	2023-04-12
BG113148A (bg)	2021-12-15

Publication	Publication Date	Title
Ignacio et al.	2016	Correlation between body mass index and faecal microbiota from children
Rigsbee et al.	2012	Quantitative profiling of gut microbiota of children with diarrhea-predominant irritable bowel syndrome
Morelli	2014	Yogurt, living cultures, and gut health
Bridgman et al.	2016	Gut microbiota and allergic disease in children
Cecchini et al.	2013	Functional metagenomics reveals novel pathways of prebiotic breakdown by human gut bacteria
Tuzun et al.	2013	Breast milk jaundice: effect of bacteria present in breast milk and infant feces
US20150104423A1 (en)	2015-04-16	Use of blood group status iii
Dennis-Wall et al.	2017	Probiotics (Lactobacillus gasseri KS-13, Bifidobacterium bifidum G9-1, and Bifidobacterium longum MM-2) improve rhinoconjunctivitis-specific quality of life in individuals with seasonal allergies: a double-blind, placebo-controlled, randomized trial
WO2012013861A2 (fr)	2012-02-02	Utilisation de statut de groupe sanguin de type iii
Song et al.	2022	An investigation into the correlation of intestinal flora with obesity and gestational diabetes mellitus
Rubio-del-Campo et al.	2020	Human milk and mucosa-associated disaccharides impact on cultured infant fecal microbiota
Rosendale et al.	2012	Characterizing kiwifruit carbohydrate utilization in vitro and its consequences for human faecal microbiota
Park et al.	2021	Comprehensive analysis of the effect of probiotic intake by the mother on human breast milk and infant fecal microbiota
Damé-Teixeira et al.	2020	Gene expression profile of Scardovia spp. in the metatranscriptome of root caries
CN114728028A (zh)	2022-07-08	包括具有增强的持久性的新微生物的组合物、新微生物和益生元的协同组合
Ingribelli et al.	2023	Culture-dependent screening of endospore-forming clostridia in infant feces
BG113148A (bg)	2021-12-15	Метод за количествена оценка за бързо прогнозиране и контрол на дисбиози на стомашно-чревния тракт при кърмачета на възраст до една година и за многофакторни заболявания
Mollova et al.	2024	In vitro Digestion: Exploring the probiotic abilities and metabolization of human milk oligosaccharides by two strains of Limosilactobacillus fermentum isolated from breast milk
Zhu et al.	2021	Comparison between the molecular diagnostic test and chest X-ray combined with multi-slice spiral CT in the diagnosis of lobar pneumonia
Nalage et al.	2022	First Three Days of Life
Picaud et al.	2025	Partially hydrolyzed, whey-based infant formula with six human milk oligosaccharides, B. infantis LMG11588, and B. lactis CNCM I-3446 is safe, well tolerated, and improves gut health: a staged analysis of a randomized trial
Valdés et al.	2013	Population dynamics of some relevant intestinal microbial groups in human fecal batch cultures with added fermentable xylooligosaccharides obtained from rice husks
Chaima et al.	2022	Association between intestinal bacterial carriage, biomarkers of environmental enteric dysfunction, and stunting in rural Malawian children
Terauchi	2024	Investigating the Role of the Gut Microbiome and the Gut Metabolome in the Development of Childhood Eczema and Asthma
Odenwald et al.	2023	Prebiotic activity of lactulose optimizes gut metabolites and prevents systemic infection in liver disease patients